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Background: There are few published health technology assessments that have included the impact of a disease
or treatment on caregivers’ health related quality of life (HRQL). The objectives of this study were to explore the
overall HRQL of caregivers of people with Multiple Sclerosis compared to matched controls, and more specifically
explore the impact of different levels of functioning in people with MS on caregivers’ HRQL scores.
Methods: A cross sectional observational study conducted as an online survey was undertaken in the UK.
200 caregivers of people with MS and 200 matched controls completed the EQ-5D, SF-36, HADS and a socio-
demographic questionnaire. Caregivers also completed the Patient Determined Disease Steps questionnaire as
a measure of MS severity. Differences in HRQL between caregivers and controls were assessed using t-tests and
chi square analyses as appropriate. Ordinary Least Squares regression was also used to evaluate the disutility of
being a caregiver compared to controls stratified by MS severity.
Results: Caregivers reported significantly lower HRQL, as measured by the SF-36, HADS and EQ-5D, compared to
matched controls. A lower level of functioning in people with MS was mirrored by lower levels of caregivers’ HRQL.
At the point at which mobility problems required wheelchair use caregivers reported better HRQL.
Conclusions: The potential impact of caregiving on HRQL is an important consideration for economic evaluations.
In relation to MS, the results suggest that caregiver’s HRQL deteriorates as the people with MS lose functioning;
thus treatments that delay loss of function may have a benefit for caregivers as well as patients.
Keywords: Health related quality of life, Burden of illness, Multiple sclerosis, Disease severity, Indirect costsBackground
Caring for partners, dependents or relatives with chronic
disease can have a substantial impact on the health of the
caregiver [1-3]. This has been recognised by policy makers
and the UK Department of Health (DH). A standing com-
mission on caregivers was established in 2009 and the DH
has been promoting a national strategy for caregivers since
1999. The physical and emotional impact associated with
being a caregiver is also recognised by the National Institute
for Health and Clinical Excellence (NICE) in their review of
the cost effectiveness of new therapies. The NICE methods* Correspondence: sarah@acaster.org
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reproduction in any medium, provided the orguide (2013) for manufacturers’ highlights how the indirect
impact of a disease or treatment on caregivers can be con-
sidered when assessing the cost effectiveness of therapies. A
treatment that maintains or improves a caregivers’ health
related quality of life (HRQL) is a relevant benefit to be
considered in an economic evaluation. NICE use relevant
HRQL data (in the form of a utility) to estimate quality
adjusted life years in cost utility analysis and has a prefe-
rence for the EQ-5D [4].
Despite this, the impact of caregiving on health has in-
frequently been considered in health technology assess-
ments (HTA) in the UK. Two reviews of outcomes data
included in NICE appraisals [5,6] make no reference to
any appraisals that directly included caregiver HRQL data.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Acaster et al. BMC Health Services Research 2013, 13:346 Page 2 of 8
http://www.biomedcentral.com/1472-6963/13/346Two appraisals (for Alzheimer’s disease and Multiple
Sclerosis) included adjustments to mean utility values to
represent the effect of treatment on carers HRQL, and
both utilized the same Alzheimer’s caregiver data. From
an economic evaluation perspective this seems to be an
under researched area [7-9]. However, given the high
prevalence of unpaid caregivers in a range of therapy areas
we believe more work is needed. Further discussion of
the role and importance of caregiving has recently been
called for [10].
The present study aimed to measure the impact on
HRQL of being an unpaid caregiver of someone with
Multiple Sclerosis (MS) including the EQ-5D as the
measure preferred by NICE for economic evaluations.
Previous research has demonstrated the negative impact
on HRQL of being a caregiver to a person with MS, with
added burden associated with increased disease severity
[11-14]. However, to the authors’ knowledge, no explor-
ation of the potential for this impact to be captured by
preference based utility measures suitable for economic
analysis, such as the EQ-5D, has been conducted to date.
Thus, the aim of the present study was to explore the
overall HRQL of caregivers of people with MS includ-
ing a utility measure compared to matched controls,
and more specifically explore the impact of different
levels of functioning in people with MS and how that
related to caregiver’s HRQL compared to matched
controls. This study was exploratory and was designed as
a cross sectional survey of caregivers of people with




A cross sectional observational study conducted as an
online survey was undertaken in the UK. 200 caregivers
and 200 controls, matched on age, sex, employment sta-
tus and habitation status, were recruited from the ge-
neral population using a specialist patient recruitment
panel. Response rates were 75% for caregivers (200/266)
and 95% for the general population (200/211). All care-
givers reported providing unpaid care to a person with
MS on a daily basis, information regarding the type of
activities and time spent daily providing care were collected
for descriptive purposes but not utilised for screening
purposes or statistical analyses. All controls were screened
to ensure they did not provide unpaid care to an individual
\with any disease or disorder.
Ethics
Independent ethical review was sought and granted by
Schulman Associates Institutional Review Board Inc.
Informed written consent was obtained from all partici-
pants prior to completion of the online survey.Survey
Potential participants were sent an email asking if they
would be interested in participating in a survey that
would involve answering some questions about them-
selves (and the person they cared for, if a caregiver). In-
terested participants followed a link provided in the
email to get to the consent form, screening questions,
and the survey. Caregivers were recruited first, followed
by the general population control group, in order to
match the two groups on the socio-demographic vari-
ables detailed above. The survey was conducted in
March 2010.
The HRQL measures included the EQ-5D [15,16]; the
SF-36 [17], and the Hospital Anxiety and Depression
Scale (HADS; [18]). Caregivers only were also asked to
complete the Patient Determined Disease Steps Scale
(PDDS; [19-22]). The PDDS is a self-complete tool
which is designed to provide an assessment of functional
loss in MS. It was used here to stratify the disease seve-
rity of the people the caregivers were providing care for.
All participants also completed a socio-demographic
form. Each of these measures is described in more detail
below.
The EQ-5D is a generic health status measure. Partici-
pants indicate their current health status on five domains
(mobility; self-care; usual activity; pain/discomfort;
anxiety/depression) as either no problems, some prob-
lems or severe problems. Participants also indicate their
current health on a visual analogue scale. Health utilities
were derived from the EQ-5D using UK general popula-
tion preference weights [23], which provide a potential
range of scores from - 0.59 to 1.0 (where a score of 1
represents full health and a score of 0 represents dead).
The SF-36 Version 2 (4 week recall period) is a generic
HRQL instrument. It is intended for use in a wide range
of conditions as well as the general population, and can
be self-administered. There are 36 items that assess
health across 8 domains: bodily pain, general health per-
ceptions, mental health, physical functioning, role limita-
tions due to emotional health problems, role limitations
due to physical health problems, social functioning, and
vitality. All items use categorical response options (range:
2–6 options). Two component summary scores for phys-
ical and mental health can also be calculated. The scores
for each subscale are converted to norm based scores
(based on 1998 US general population), with a mean of 50
and a standard deviation of 10. A score of 100 represents
the best health.
The HADS is a self-administered measure of anxiety
and depression. It has 14 items divided equally between
two subscales; the HADS-A (Anxiety subscale) and the
HADS-D (Depression subscale). Each item is rated on a
4-point scale (0 = not at all, to 3 = yes definitely), thus
each subscale has a score ranging from 0–21. Research
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fined by a cut off score of ≥ 8 [24].
The PDDS is a self-assessment scale that assesses
functional disability in people with MS. It is based on
the earlier clinician rated Disease Steps Scale (DSS) de-
veloped by [19], which maps to the Expanded Disability
Severity Scale, EDSS [25]. In line with the EDSS, the
PDDS is a 9 point scale focusing mainly on mobility: 0
(normal) to 8 (bedridden; see Table 1 for a detailed
description of each level). The wording of the PDDS was
slightly modified, with the developer’s permission, from a
patient reported instrument to a caregiver proxy instru-
ment for the purposes of this study.
The socio-demographic form included questions related
to age, gender, ethnicity, educational level, employment
status, living situation and whether they suffer from any
illnesses. The caregivers were also asked questions about
their role as a caregiver and the person they care for, for
example, how long they have been a caregiver, their rela-
tionship to the person with MS, how many hours of care
they provide per day, what type of MS the person they
care for has, what type of activities they help with, and
whether they get any support themselves.
Statistical analysis
The caregiver and control groups’ socio-demographic de-
tails were tabulated and analysed for any significant
between group differences using t-tests or chi square ana-
lyses as appropriate. The SF-36 and HADS questionnaires
were scored according to their published scoring instruc-
tions. Any potential HRQL differences between caregivers
and controls, as measured by these instruments, wereTable 1 Patient determined disease steps
0 Normal: The person that I care for may have some mild symptoms, m
does have an attack, he/she returns to normal when the attack has pa
1 Mild Disability: The person that I care for has some noticeable sympt
his/her lifestyle.
2 Moderate Disability: The person that I care for doesn’t have any limi
problems due to MS that limit daily activities in other ways.
3
Gait Disability: MS does interfere with his/her activities, especially his
demanding activities are more difficult than they used to be. He/she u
need some assistance during an attack.
4
Early Cane: The person that I care for uses a cane or a single crutch o
someone’s arm) for walking all the time or part of the time, especially
without a cane or crutch. He/she always needs some assistance (cane
5
Late Cane: To be able to walk 25 feet, the person that I care for has t
the house or other buildings by holding onto furniture or touching th
wants to go greater distances.
6 Bilateral Support: To be able to walk as far as 25 feet the person tha
scooter or wheelchair for longer distances.
7 Wheelchair/Scooter: His/her main form of mobility is a wheelchair. H
can’t walk 25 feet, even with crutches or a walker.
8 Bedridden: The person that I care for is unable to sit in a wheelchairassessed using independent t-tests, effect size calculations
and chi square analyses as appropriate.
Health utilities were derived from the EQ-5D using
validated scoring instructions and UK general population
weightings [23]. The difference in EQ-5D utility values
between groups was assessed using an independent t-
test. Ordinary least squares regression was used to fur-
ther examine the group differences with the caregiver
population stratified by MS severity, as measured by the
PDDS. Eight groups were created (controls and PDDS
0–1; 2–3; 4; 5; 6; 7; 8) and dummy coded with the con-
trols as the reference category [26]. PDDS groups 0 and
1, and 2 and 3 were collapsed due to small sample sizes
in individual categories (n < 10). Socio-demographic vari-
ables were included in the model as covariates, as the
caregivers and controls were only matched at the group
level; thus creating variability once the caregiver sample
was stratified by MS severity. All analyses were conducted
in SPSS version 18.
Results
The socio-demographic data for the control and caregiver
samples are presented in Table 2. In line with the sam-
pling methodology there were no significant differences
in age, gender, education, employment or living status
between groups. Similarly, there were no group differences
in the proportion of people reporting a number of com-
mon diseases or disorders: heart disease, arthritis, diabetes
or cancer. However, there were significantly higher inci-
dences of self-reported psychological problems amongst
the caregiver population compared to controls: stress
(χ2 = 41.0, p < .001), anxiety (χ2 = 20.8, p < .001), depressionostly sensory due to MS but these do not limit his/her activity. If he/she
ssed.
oms from his/her MS but they are minor and have only a small effect on
tations in his/her walking ability. However, he/she does have significant
/her walking. He/she can work a full day, but athletic or physically
sually doesn’t need a cane or other assistance to walk, but he/she might
r some other form of support (such as touching a wall or leaning on
when walking outside. I think he/she can walk 25 feet in 20 seconds
or crutch) if he/she wants to walk as far as 3 blocks.
o have a cane, crutch or someone to hold onto. He/she can get around
e walls for support. He/she may use a scooter or wheelchair if he/she
t I care for must have 2 canes or crutches or a walker. He/she may use a
e/she may be able to stand and/or take one or two steps, but he/she
for more than one hour.
Table 2 Socio-demographic descriptive statistics for control and caregiver groups
Characteristic Controls Caregivers
N 200 200
Age Mean (SD) 50.99 (13.80) 50.88 (13.48)
Gender Male N (%) 106 (53.0%) 109 (54.5%)




95 (47.5%) 99 (49.5%)
University 70 (35.0%) 66 (33.0%)




66 (33.0%) 63 (31.5%)
Employed part-time 28 (14.0%) 29 (14.5%)
Retired 62 (31.0%) 64 (32.0%)




179 (89.5%) 181 (90.5%)
Living alone 6 (3.0%) 6 (3.0%)




44 (22.0%) 106 (53.0%)
Anxiety 32 (16.0%) 72 (36.0%)
Depression 32 (16.0%) 60 (30.0%)
Fatigue 37 (18.5%) 101 (50.5%)
Sleep problems 48 (24.0%) 88 (44.0%)
Heart disease 11 (5.5%) 13 (6.5%)
Arthritis 44 (22.0%) 33 (16.5%)
Diabetes 17 (8.5%) 21 (10.5%)
Cancer 5 (2.5%) 3 (1.5%)
N = Sample Size; SD = Standard Deviation.
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problems (χ2 = 17.8, p < .001).
Background characteristics of the MS caregivers and
patients they care for revealed considerable variability
(Table 3). The majority of caregivers provided assistance
with various activities of daily living and care for 5–24 hours
per day, and received no formal support.
As shown in Figure 1, the MS caregivers’ health related
quality of life was lower than the socio-demographically
matched controls on all domains of the SF-36. The group
comparisons were statistically significant across all do-
mains and summary scores, with the greatest differences
seen in relation to mental health and physical and social
functioning. Similarly, the HADS results showed that
caregivers of people with MS reported significantly higher
levels of anxiety and depression than controls. Further-
more in terms of probable clinical ‘caseness’, the HADS
scores demonstrated that, the caregiver population
contained a significantly greater proportion of probable
anxiety ‘cases’ (χ2 = 38.83, p < .001) and depression cases
(χ2 = 25.71, p < .001). The frequency of anxiety and de-
pression probable clinical cases by population is presented
in Table 4.The EQ-5D utility values also demonstrated a significant
difference between the controls and caregivers of people
with MS: M = 0.82, SD = 0.25 and M= 0.74, SD = 0.28, re-
spectively [t (398) = 2.99, p = .003]. The estimated disutility
values associated with being a caregiver relative to the
control population, stratified by PDDS MS severity and
with all socio-demographic variables considered as covari-
ates, are presented in Figure 2. These show lower care-
giver utility compared to controls in line with greater
loss of functioning in people with MS. At PDDS 0–1
the difference between caregivers and controls is neg-
ligible (− 0.002, SE = 0.053), increasing at PDDS 2 – 3
(− 0.045, SE = 0.057) and showing significant diffe-
rences between caregivers and controls at PDDS levels 4, 5
and 6, [disutility - 0.142 (SE = 0.062), - 0.160 (SE = 0.055), -
0.173 (SE = 0.054), respectively]. At PDDS level 7 (a level
where the person with MS would typically require use of a
wheelchair) the caregiver’s quality of life is less affected
(PDDS 7: - 0.030, SE = 0.038) and appears in line with dis-
utility at PDDS 2 – 3. This is also true at PDDS 8 where
the person with MS would be predominantly bedridden
(PDDS 8: - 0.095, SE = 0.075). As illustrated by the error
bars in Figure 2 (+ / - 1.96 * SE), only PDDS groups 4, 5
Table 3 Caregiver and caregiver-reported MS characteristics
Characteristic Distribution
Length of time as caregiver (years) Mean (SD) 9.57 (8.47)
Length of time individual has had MS (years) Mean (SD) 14.93 (12.83)
Type of MS
Relapsing Remitting MS (RRMS)
N (%)
50 (25.0%)
Secondary Progressive MS (SPMS) 87 (43.5%)



















Family Other 19 (9.5%)
Friend 11 (5.5%)
Live with the person you provide care for? Yes N (%) 168 (84.0%)
Number of hours a day providing care 1 - 4
N (%)
55 (27.5%)
5 - 9 46 (23.0%)
10 - 24 99 (49.5%)
Help with activities of daily living







Getting around inside the home 104 (52.0%)






External formal care giver 51
N = Sample Size; SD = Standard Deviation; * See Table 1 for description of PDDS levels.
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the control population.
Post hoc analyses were conducted to explore the re-
duced disutility at PDDS 7 and 8 by evaluating the im-
pact of receiving external caregiver support including
professional assistance from social services. No diffe-
rence in utility values were found for caregivers recei-
ving versus not receiving support (M = 0.76, SD = 0.23
and M = 0.77, SD = 0.22, respectively).Discussion
This study aimed to explore the HRQL of caregivers of
people with MS compared to matched controls. There
was a particular interest in the impact of disease severity
on the disutility associated with being a caregiver com-
pared to controls, due to the paucity of caregiver data
currently being considered in economic analyses. The
results demonstrated that caregivers of people with MS






















Figure 1 SF-36 and HADS descriptive statistics and between groups analysis. (royal purple bar) SF – 36 control mean, (lavender bar) SF – 36
caregiver mean, (dark olive green bar) HADS control mean, and (pistachio bar) HADS caregiver mean. PCS = physical component summary,
MCS = mental component summary, GH = general health domain, VT = vitality domain, SF = social functioning domain, PF = physical functioning
domain, RE = role emotional, RP = role physical, MH = mental health domain, BP = bodily pain domain. *p < 0.05; **p < 0.01; ***p < 0.001.
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trols. There was also a significantly greater proportion of
HADS anxiety and depression clinical cases amongst
caregivers compared to matched controls. Furthermore,
lower levels of functioning in people with MS was mir-
rored by lower levels of caregiver’s HRQL up until the
point at which mobility problems required wheelchair
use. However, once caregiver reported MS severity had
progressed to this point the difference in health utility
scores between caregivers and controls reduced, indica-
tive of better caregiver HRQL at the most advanced
levels of MS severity. The reason for this is unclear and
while post hoc analyses suggested that this was not due
to reduced burden from external caregiver support, thisTable 4 Frequency of HADS anxiety and depression
‘cases’ by study population
Controls Caregivers
n (%) n (%)
HADS Anxiety Probable Clinical Case* 59 (29.5%) 121 (60.5%)
HADS Depression Probable Clinical Case* 39 (19.5%) 86 (43.0%)
*Score ≥ 8 = probable clinical case [24].and other potential explanations could be usefully fur-
ther researched in a longitudinal study.
The significant impact of providing care on HRQL
demonstrated here provides support for the need to con-
sider caregivers’ HRQL in economic assessments of new
health technologies. Furthermore, contrary to concerns
expressed by Al-Janabi et al. [7], the results also suggest
that in line with the NICE reference case the EQ-5D
may be an appropriate measure to capture caregiver
HRQL (2013). However, we also believe that there may
be merit in conducting further research into the deve-
lopment of a caregiver specific measure to capture their
specific concerns. The high level of variability seen in
the EQ-5D utility scores at each PDDS level suggests
that core concepts associated with being a caregiver to a
person with MS may not currently be captured by the
EQ-5D, and this could be explored through qualitative
research. For example, the pattern of disutility captured
by the EQ-5D here suggests the potential physical and
psychological impact associated with caring for an indi-
vidual who is bedridden may not be captured by the
EQ-5D. Another potential explanation for the reduced
disutility observed with increased disease severity found



































Caregiver Reported MS Severity Level: PDDS 
Figure 2 EQ-5D utility decrement associated with caregivers compared to controls by MS severity level (error bars represent 1.96 × SE).
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rent study design would be needed to address this hy-
pothesis properly.
The results from the current study reflect a different pat-
tern of HRQL impact than the values used in the NICE
HTA submission in MS that utilised caregiver data [6]. That
assessment assumed significant disutility only occurred at
the very severe stages of MS; an assumption based on data
from caregivers of people with Alzheimer’s disease. While
the current findings are exploratory and need to be consi-
dered in light of the study limitations and the potential limi-
tations of the EQ-5D to assess HRQL in caregivers, they
do suggest that caregiver HRQL is impacted earlier in
disease progression than previously indicated. Thus, care-
giver utility data may be an important consideration in the
evaluation of new MS treatments associated with slowing
MS progression from relatively early stages of disease.
Limitations
Given the exploratory nature of this study there are some
limitations that need to be considered. Primarily, this was
a cross sectional study of a progressive disease, and ideally
the disutility of providing care should be measured longi-
tudinally in order to capture potential within person
changes over time. Additionally, due to the cross sectional
nature of the study there were also uneven numbers in
the different PDDS groups, with particularly small sample
sizes in PDDS 8 for the stratified analysis. Variability in pa-
tient symptoms, and therefore the exact type of care pro-
vided, beyond those captured by the PDDS were also not
considered in the stratified PDDS analysis and these may
have a direct impact on the caregivers HRQL. Finally, aproxy version of the PDDS was used, with the caregivers
reporting on their perception of the MS severity of the
person they provide care for rather than the people with
MS themselves. This caregiver reported version of the
PDDS has not been correlated with the patient-reported
PDDS and therefore may be a source of error if the utility
values presented here are applied to patient reported data.
However, given the concrete nature of the PDDS classifi-
cations this is likely to have a minimal impact.
Conclusions
This study has provided evidence of the significant nega-
tive impact caregiving can have on HRQL and supports
the potential consideration of caregiver HRQL in eco-
nomic assessments of new treatments. The results also
suggest that the EQ-5D is an appropriate measure of care-
giver HRQL, but given the exploratory nature of the study
and the pattern of disutility associated with MS severity
reported here; further research into the measurement of
caregiver HRQL is also warranted. In relation to MS, the
findings reported here suggest the impact of disease pro-
gression on caregiver HRQL should be considered rela-
tively early when evaluating new treatments. Issues
relating to exactly how caregiver disutility should be incor-
porated into economic assessments and consideration of
other pertinent issues, such as cultural differences related
to caregiving, also require further consideration.
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